Close menu




March 29th, 2021 | 08:15 CEST

Cardiol Therapeutics, Bayer, Formycon: These pharma stocks could explode!

  • Biotechnology
Photo credits: proactiveinvestors.com

According to official statistics, diseases of the cardiovascular system, such as heart failure, coronary heart disease or myocardial infarction, are the No.1 cause of death in Germany. With 18.2 million deaths, they represented the most common cause of death worldwide in 2019. Thus, on a global average, a good 30% of all deaths are attributable to cardiovascular disease. In Europe, more than 4 million people die each year due to such a disease, 1.4 million of whom are younger than 75. But there are many other dangers to our health. Reason enough to take a closer look.

time to read: 3 minutes | Author: André Will-Laudien
ISIN: CA14161Y2006 , DE000BAY0017 , DE000A1EWVY8

Table of contents:


    Cardiol Therapeutics - Focus on heart disease

    The causes of cardiovascular diseases are manifold and can be divided into influenceable and non-influenceable risk factors. Non-influenceable risk factors include age, gender and genetic predisposition. Influenceable risk factors include high blood pressure, diet, diabetes, obesity, smoking, lack of exercise, and excessive alcohol consumption, the scourges of modern society.

    A distressing combination occurs when simple flu-like infections combined with stress-related factors result in severe heart muscle inflammation. Canadian biotechnology Company Cardiol Therapeutics has focused on the research and development of anti-inflammatory therapies to treat cardiovascular disease. The Company's lead product is CardiolRx™, a proprietary pharmaceutically produced high-concentration, ultra-pure oral cannabidiol (“CBD”) formulation.

    Of interest now are the ongoing tests with COVID-19 patients who are available for a clinical trial. Especially in the area of currently emerging mutations, the combination of cardiac symptoms and acute pulmonary dysfunction can carry a significant risk of death. A Phase 1 trial has already been completed with CardiolRx™. The hope now is that this CBD formulation can be a cardioprotective therapy to reduce mortality and major cardiovascular events in COVID-19 patients who have a prior history of, or risk factors for, cardiovascular disease.

    Cardiol Therapeutics has addressed attractive areas with its current research pipeline, which could multiply the current market capitalization of EUR 100 million if the related success stories are reported. Therefore, take the stock, which is also traded in Germany, into your shortlist.

    Bayer - The search for final settlements

    In 2020, chemical Company Bayer posted the highest loss in its corporate history due to its acquisition of US seed and pesticide producer Monsanto. The Leverkusen-based Company last reported a net loss of EUR 10.5 billion, mainly due to "special charges" of EUR 23 billion. These relate to provisions for lawsuits concerning the Monsanto pesticides, glyphosate and dicamba, the industrial chemical PCB which the US company also produces, and the sterilization spiral Essure.

    Some 125,000 plaintiffs blame Monsanto's weedkiller Roundup, which contains the active ingredient glyphosate, for their cancer and are seeking damages. Farmers in the US also blame Monsanto because dicamba has drifted off their neighbors' fields and damaged crops. In the US, some 40,000 women are also suing Bayer, claiming that Essure caused them to suffer injuries to their uterus and fallopian tubes, among other things.

    After years of litigation, the chemical Company has accepted the first US court ruling that the world's best-selling pesticide glyphosate caused cancer. This ruling makes the guilty verdict against the Company legally binding, and Bayer says it has already paid Johnson his USD 20.5 million in damages. German farmers also regularly use glyphosate in their fields. The EU is currently considering whether to extend or allow the approval of the controversial agent to expire.

    For Bayer shares, the decision will soon be made because, after a low of around EUR 40, resistance at EUR 56 is now on the horizon. Prices above this would open up the potential to EUR 80.

    Formycon - Also well equipped for COVID-19

    Some time ago, the biosimilar manufacturer Formycon attracted attention with an application against COVID-19. There is news on the active ingredient FYB207, which has recently been in the spotlight mainly due to tests for use against coronaviruses. The in vitro neutralization of SARS-CoV-2 variants by FYB207 show that the active ingredient has an even stronger effect against the B.1.1.7 mutant of the virus, which is considered particularly infectious, than against earlier variants. This is excellent news in the fight against the pandemic.

    SARS-CoV-2 and other coronaviruses use the protein ACE2 on human cells' surface as an entry portal for respiratory infections. Formycon has therefore fused the human ACE2 protein to the constant portion of human immunoglobulin G4 (IgG4) using computational structural design, creating a very effective SARS-CoV-2 blocker that completely prevents cell infection in vitro.

    However, FYB207 is still far from potential approval as a drug. According to the Company, preclinical activities and preparations for entering clinical trials with FYB207 are fully on track. Still, experience has shown that the trials are lengthy and costly in their design. In our opinion, a clinical phase may already occur in the second half of 2021. The share has consolidated up to EUR 58 and is now gaining new momentum.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    André Will-Laudien

    Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

    About the author



    Related comments:

    Commented by André Will-Laudien on June 30th, 2022 | 13:49 CEST

    Biotech blockbusters: BioNTech, XPhyto Therapeutics, Valneva, CureVac - What to expect from these stocks?

    • Biotechnology

    Now that we have arrived in summer, the pandemic is weakening, and the media presence of the flu disease is also declining. That means less attention for pure-play vaccine makers, and now investors are asking how perhaps alternative money can be made. Is the pipeline of the protagonists strong enough to attract further investor capital, or will the whole industry go underground for the time being? We try our hand at being a truffle pig and dig beneath the surface. Which biotech stock has something up its sleeve?

    Read

    Commented by Stefan Feulner on June 27th, 2022 | 12:12 CEST

    BrainChip and Palantir with strong rebound - How does BioNTech react?

    • chips
    • Technology
    • Biotechnology

    The correction on the stock markets has been going on for months. Technology stocks, in particular, have been hit hard. Due to the end of the ultra-loose monetary policy and possible larger interest rate steps, even market leaders lost more than 80% of their ground in some cases. Whether interest rate hikes can be implemented as planned in the coming months, on the other hand, appears more than questionable. After all, the spectre of recession is already hovering over the capital markets. Moreover, the historical debt levels of several countries are likely to rule out further interest rate hikes.

    Read

    Commented by Fabian Lorenz on June 23rd, 2022 | 11:35 CEST

    Takeover fantasy: +50% in Valneva shares, and what are BioNTech and Defence Therapeutics doing?

    • Biotechnology
    • Pharma

    Tension is rising in the biotech sector as the takeover merry-go-round spins faster and has now hit Valneva. Pfizer's entry caused the stock to explode 50% in three trading days. Earlier, Pfizer had announced it would acquire migraine specialist Biohaven for USD 11.6 billion. Other pharmaceutical giants are also active: Halozyme wants to swallow Antares Pharma, a specialist in urology and endocrinology, for USD 960 million. The acquisition of Sierra Oncology is costing GlaxoSmithKline around USD 1.9 billion. Like Valneva, Defence Therapeutics is about to start important trials and could attract a major partner. A takeover of BioNTech is unlikely, but the flagship German biotech should also benefit from improved sentiment in the industry. The coming week should be operationally exciting for shareholders.

    Read